<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00485108</url>
  </required_header>
  <id_info>
    <org_study_id>DJ1</org_study_id>
    <nct_id>NCT00485108</nct_id>
  </id_info>
  <brief_title>Anti-inflammatory Therapy Following Selective Laser Trabeculoplasty</brief_title>
  <official_title>Anti-inflammatory Therapy Following Selective Laser Trabeculoplasty (SLT): A Randomized, Masked, Placebo Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen's University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Glaucoma Research Society of Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Queen's University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The type of anti-inflammatory medication used post selective laser trabeculoplasty (SLT) may
      have an impact on the intra-ocular pressure (IOP) lowering effect of SLT. This study will
      evaluate the IOP lowering effect of SLT following the topical administration of one of the
      following: prednisolone 1%, ketorolac 0.5% or artificial tears.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who have been chosen to undergo SLT for glaucoma will be randomized to receive one
      of prednisolone 1%, ketorolac 0.5% or artificial tears four times a day for 5 days following
      administration of the laser treatment. The IOP will be measured at various time points
      following SLT: 1 hour, 2 days, 1 week, 1 month, 3 months, 6 months, and 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular pressure lowering effect</measure>
    <time_frame>1 hour, 2 days, 1 month, 3 months, 6 months and 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>intraocular pressure elevation</measure>
    <time_frame>1 hour, 2 days, 1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <condition>Pseudoexfoliation Glaucoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prednisolone 1% eye drop</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ketorolac 0.5% eye drop</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Artificial Tears (methyl cellulose eye drop)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisolone 1%</intervention_name>
    <description>eye drop once in each eye treated, 4 times / day for 5 days post-laser</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ketorolac 0.5%</intervention_name>
    <description>eye drop once in each eye treated, 4 times / day for 5 days post-laser</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Acular</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artificial Tears (Methyl cellulose drops)</intervention_name>
    <description>eye drop once in each eye treated, 4 times / day for 5 days post-laser</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Refresh Tears</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  primary open angle glaucoma, pseudo exfoliation glaucoma

        Exclusion Criteria:

          -  previous incisional glaucoma surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rob J Campbell, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen's University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Delan Jinapriya, MD</last_name>
    <role>Study Director</role>
    <affiliation>Queen's University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen's University</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2007</study_first_submitted>
  <study_first_submitted_qc>June 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2007</study_first_posted>
  <last_update_submitted>September 21, 2015</last_update_submitted>
  <last_update_submitted_qc>September 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Queen's University</investigator_affiliation>
    <investigator_full_name>Dr. Robert Campbell</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>primary open angle glaucoma</keyword>
  <keyword>pseudoexfoliation glaucoma</keyword>
  <keyword>selective laser trabeculoplasty</keyword>
  <keyword>intra ocular pressure</keyword>
  <keyword>anti-inflammatory therapy</keyword>
  <keyword>prednisolone acetate 1%</keyword>
  <keyword>ketorolac tromethamine 0.5%</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Exfoliation Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Lubricant Eye Drops</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

